gastric juice protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
A collaboration between Fred McLafferty and Roland Gohlke and William C. Wiley and Daniel B. Harrington of Bendix Aviation in the 1950s led to the combination of gas chromatography and mass spectrometry, and the development of Gas chromatography–mass spectrometry instrumentation. Beginning in the 1960s, Bendix produced scientific instruments such as the Bendix MA-2 Time-of-Flight Mass Spectrometer.
Alexandra C. Newton is a Canadian and American biochemist. She is a Distinguished Professor of pharmacology at the University of California, San Diego. Newton runs a multidisciplinary Protein kinase C and Cell signaling biochemistry and cell biology research group in the School of Medicine, investigating molecular mechanisms of signal transduction in the Phospholipase C (PLC) and Phosphoinositide 3-kinase (PI3 kinase, or PI3-K) signaling pathways. She has been continuously funded by the US National Institutes of Health since 1988. Newton was born in Cape Town, South Africa, and was schooled in Vancouver, Athens, and Aix-en-Provence. She graduated in 1980 from the Simon Fraser University in Canada, where she was awarded a 1st-class honours degree in biochemistry and French literature. She received her PhD in chemistry in 1986 from Stanford University, working with Wray H. Huestis on a thesis examining band 3, a red cell membrane protein.
Cadmium is a strong neutron poison and in fact control rods are often made out of cadmium, making the accumulation of cadmium in fuel of particular concern for the maintenance of stable neutron economy. Cadmium is also a chemically poisonous heavy metal, but given the number of neutron absorptions required for transmutation, it is not a high priority target for deliberate transmutation.
Sources: en.wikipedia.org
=== Ketchup === Ketchup is a shear thinning fluid. Shear thinning means that the fluid viscosity decreases with increasing shear stress. In other words, fluid motion is initially difficult at slow rates of deformation, but will flow more freely at high rates. Shaking an inverted bottle of ketchup can cause it to transition to a lower viscosity through shear thinning, making it easier to pour from the bottle.
== Match records == Highest score: 32.16 (208) v Footscray 9.8 (62) – Round 22, 1982, at Western Oval Lowest score: 0.9 (9) v Fitzroy 6.11 (47) – Round 1, 1899, at Brunswick Street Oval Lowest score since 1919: 1.12 (18) v St Kilda 5.5 (35) – Round 10, 1923, at Junction Oval Highest losing score: Essendon 21.13 (139) v Collingwood 23.6 (144), Round 22, 1987, M.C.G. Lowest winning score: Essendon 1.8 (14) v Melbourne 0.8 (8), Finals Week 3, 1897, Lake Oval (League record) Lowest winning score since 1919: Essendon 3.10 (28) v Footscray 3.5 (23), Round 13, 1989, Windy Hill Greatest winning margin: 165 points – Essendon 28.16 (184) v South Melbourne 2.7 (19), Round 18, 1964, Windy Hill Greatest losing margin: 163 points – Essendon 11.7 (73) v Sydney Swans 36.20 (236), Round 17, 1987, S.C.G. Record attendance (home-and-away game): 94,825 – 25 April 1995 at MCG v Collingwood (inaugural Anzac Day match) Record attendance (finals match): 116,828 – 1968 VFL Grand Final v Carlton
=== Skin depigmentation === Hydroquinone is used topically for skin whitening, either alone or in combination with other topical agents. It is the most effective treatment for hyperpigmentation. It does not have the same predisposition to cause dermatitis as metol does. This is a prescription-only ingredient in some countries, including the member states of the European Union under Directives 76/768/EEC:1976. Its skin-lightening effect was first reported in 1936. In the 1950s, it was available as part of a sunscreen formulation in southern regions of the USA. Its skin-lightening effect was observed as a fortuitous side-effect. In 1961, it was trialed for hyperpigmentation. In 1975, a topical combination of hydroquinone 5%, tretinoin 0.1% and dexamethasone 0.1% was trialed for melasma, ephelides and postinflammatory hyperpigmentation. In 2006, United States Food and Drug Administration (FDA) revoked its previous approval of hydroquinone and proposed a ban on all over-the-counter preparations. The FDA officially banned hydroquinone in 2020 as part of a larger reform of the over-the-counter drug review process. The FDA stated that hydroquinone cannot be ruled out as a potential carcinogen. This conclusion was reached based on the extent of absorption in humans and the incidence of neoplasms in rats in several studies where adult rats were found to have increased rates of tumours, including thyroid follicular cell hyperplasias, anisokaryosis (variation in nuclei sizes), mononuclear cell leukemia, hepatocellular adenomas and renal tubule cell adenomas.
=== In the Antarctic === The first cold seep from the Southern Ocean was reported in 2005. The relatively few investigations to the Antarctic deep sea have shown the presence of deep-water habitats, including hydrothermal vents, cold seeps, and mud volcanoes. Other than the Antarctic Benthic Deep-Sea Biodiversity Project (ANDEEP) cruises, little work has been done in the deep sea. There are more species waiting to be described.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.